Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation
Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation
复制标题
单倍体相合造血干细胞移植《北京方案》更新
DOI：
10.1038/s41409-019-0605-2
复制
发表时间：
2019-08-01
影响因子：
4.8
通讯作者：
Huang, Xiao-jun
中科院分区：
文献类型：
--
作者：
Lv, Meng;Chang, Ying-jun;Huang, Xiao-jun
“北京方案”是近几十年来三种成功的单倍体干细胞移植（haploi - sct）方法之一，它基于粒细胞集落刺激因子和抗胸腺细胞球蛋白诱导的免疫耐受，包括个体化调节方案、新的供体选择算法、GvHD和复发的风险导向策略等。遵循“北京方案”的单倍造血干细胞移植显示出与hla匹配的造血干细胞移植相似的疗效，这已成为中国同种异体造血干细胞移植的主要策略，并为改进全球实践提供了灵感。本文将重点介绍该方法在以下方面的最新进展和前景：(1)从恶性血液疾病到非恶性疾病的适应症；(2)造血恢复微环境；(3)改善T细胞功能。
As one of the three successful approaches for haplo-identical stem cell transplantation (haplo-SCT) in recent decades, "Beijing protocol" was based on immune tolerance induced by granulocyte colony-stimulating factor plus anti-thymocyte globulin, which included individualized conditioning regimens, novel donor selection algorithm, and risk-directed strategies for GvHD and relapse, etc. Haplo-HSCT following "Beijing protocol" demonstrated similar efficacy to HLA-matched SCT, which has become the predominant strategy for allogeneic SCT in China as well as inspiration for refinement of global practice. This review will focus on recent progressions and prospective of this approach in (1) the indications from hematological malignancies to non-malignant diseases; (2) microenvironment for hematopoietic recovery; and (3) improving T cells function.